SELECXINE

Precision Immune Modulation for a Better Tomorrow

Founded 2018 · $12.0M raised

Employees
1–10
Founded
2018
Business Model
B2B
Total Funding
$12.0M
Last Round
$12.0M Series BJan 2022
Rounds
2

About

Selecxine develops therapeutic antibodies using proprietary discovery and conjugation technologies. Its Selectope platform combines phage-library generation, cell-based panning, epitope mapping, and antibody characterization to identify selective, functionally validated candidates. The company's pipeline includes an antibody-cytokine conjugate designed to amplify anti-tumor immune responses and additional antibody programs intended to selectively suppress inflammatory signaling while preserving beneficial immune biology.

Summary

SELECXINE is a Biotech company, founded in 2018. It has raised $12.0M in total across 2 rounds, most recently a $12.0M Series B round in Jan 2022. Investors include Stonebridge Capital, STIC Ventures and Hanwha Investment & Securities.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BJan 2022

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

SELECXINE on Indexed.vc
<a href="https://indexed.vc/companies/selecxine"><img src="https://indexed.vc/api/badge/company/selecxine" alt="SELECXINE on Indexed.vc" width="260" height="76" /></a>